Zydus Lifesciences has informed that it enclosed a copy of press release dated July 4, 2023 titled ‘Zydus receives final approval from the USFDA for Oxcarbazepine Tablets USP, 150 mg, 300 mg and 600 mg’.
The above information is a part of company’s filings submitted to BSE.